| [1] |
CUI F, SHEN L, LI L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23(5): 765-772. DOI: 10.3201/eid2305.161477. |
| [2] |
LEE HA, LEE HW, KIM IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase[J]. Aliment Pharmacol Ther, 2020, 52(1): 196-204. DOI: 10.1111/apt.15741. |
| [3] |
KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904. |
| [4] |
KUMAR M, SARIN SK, HISSAR S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology, 2008, 134(5): 1376-1384. DOI: 10.1053/j.gastro.2008.02.075. |
| [5] |
van WOLLEGHEM T, HOU J, van OORD G, et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells[J]. Hepatology, 2015, 62(1): 87-100. DOI: 10.1002/hep.27805. |
| [6] |
HONG M, BERTOLETTI A. Tolerance and immunity to pathogens in early life: Insights from HBV infection[J]. Semin Immunopathol, 2017, 39(6): 643-652. DOI: 10.1007/s00281-017-0641-1. |
| [7] |
SONNEVELD MJ, BROUWER WP, HANSEN BE, et al. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis[J]. Aliment Pharmacol Ther, 2020, 52(8): 1399-1406. DOI: 10.1111/apt.16067. |
| [8] |
ZENG HM, HAO J, CAO MM, et al. Trend analysis of age of diagnosis for liver cancer in cancer registry areas of China, 2000-2014[J]. Chin J Prev Med, 2018, 52(6): 573-578. DOI: 10.3760/cma.j.issn.0253-9624.2018.06.004. |
| [9] |
WEI KP, ZHU FC, LIU JX, et al. The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study[J]. Vaccine, 2018, 36(2): 256-263. DOI: 10.1016/j.vaccine.2017.11.037. |
| [10] |
LOU HQ, ZHU JH, WANG ZH, et al. Real-world efficacy of immunoprophylaxis against mother-to-infant transmission of hepatitis B virus based on puerperant population[J]. Chin J Perinat Med, 2019, 22(8): 591-596. DOI: 10.3760/cma.j.issn.1007-9408.2019.08.011. |
| [11] |
HUANG H, XU C, LIU L, et al. Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus[J]. Clin Infect Dis, 2020. DOI: 10.1093/cid/ciaa898.[Online ahead of print]
|
| [12] |
HU Y, FENG Z, LIU J, et al. Virological determinants of spontaneous postpartum e antigen seroconversion and surface antigen seroclearance in pregnant women infected with hepatitis B virus[J]. Arch Med Res, 2016, 47(3): 207-213. DOI: 10.1016/j.arcmed.2016.06.008. |
DownLoad: